Status:
RECRUITING
A Study on COPD Phenotypes, Endotypes and Treatable Traits
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Chronic Obstructive Pulmonary Disease (COPD)
Eligibility:
All Genders
40+ years
Brief Summary
Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous and multisystemic disease with progressive increasing morbidity and mortality. COPD is now widely accepted as a heterogeneous condition ...
Detailed Description
Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous and multisystemic disease with progressive increasing morbidity and mortality. COPD is now widely accepted as a heterogeneous condition ...
Eligibility Criteria
Inclusion
- 1\) Patient with COPD with compatible history and lung function assessment according to Global Obstructive Lung Disease (GOLD): Patient has chronic respiratory symptoms (dyspnoea, cough, sputum production and exacerbations due to abnormalities of the airway (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow limitation. Lung function assessment with forced spirometry demonstrated the presence of a post-bronchodilator FEV1/FVC \<70%.14 2) Patient with age ≥40 years
Exclusion
- Serious disease that would hinder the patient from having follow-up for 3 years, e.g. late-stage malignancy, severe heart failure and severe renal failure not on dialysis.
- Unable to provide written informed consent.
Key Trial Info
Start Date :
May 2 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 24 2030
Estimated Enrollment :
460 Patients enrolled
Trial Details
Trial ID
NCT06952881
Start Date
May 2 2025
End Date
April 24 2030
Last Update
May 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Chinese University of Hong Kong
Hong Kong, Hong Kong